Anavex Life Sciences (AVXL) Common Equity (2010 - 2025)
Anavex Life Sciences recorded quarterly Common Equity of $126.6 million in Q4 2025, up 33.47% quarter-over-quarter from $94.9 million in Q3 2025, and up 14.16% year-over-year from $110.9 million in Q4 2024.
Anavex Life Sciences' Common Equity history runs 16 years deep, the most recent figure standing at $126.6 million for Q4 2025.
- In Q4 2025, Common Equity rose 14.16% year-over-year to $126.6 million; the TTM figure through Dec 2025 stood at $126.6 million (up 14.16% YoY), while the FY2025 annual figure was $94.9 million, down 21.12% from the prior year.
- Common Equity came in at $126.6 million for Q4 2025 at Anavex Life Sciences, up from $94.9 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $157.1 million in Q2 2021 to a low of $75.8 million in Q1 2021.
- A 5-year average of $129.4 million and a median of $135.3 million in 2022 frame the typical range for Common Equity.
- Across the five-year window, Common Equity jumped 536.71% in 2021 and fell 29.91% in 2025, its largest moves.
- Anavex Life Sciences' Common Equity stood at $146.4 million in 2021, then decreased by 7.68% to $135.1 million in 2022, then gained by 0.33% to $135.6 million in 2023, then decreased by 18.19% to $110.9 million in 2024, then grew by 14.16% to $126.6 million in 2025.
- According to Business Quant data, Common Equity over the past three periods registered $126.6 million, $94.9 million, and $91.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.42 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 35.63 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 14.38 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.36 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 13.21 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.08 Bn |
| 10 | Anavex Life Sciences | 266.20 Mn | 134.45 Mn | - | 126.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 126.62 Mn |
| Sep 30, 2025 | 94.87 Mn |
| Jun 30, 2025 | 90.96 Mn |
| Mar 31, 2025 | 99.76 Mn |
| Dec 31, 2024 | 110.92 Mn |
| Sep 30, 2024 | 120.26 Mn |
| Jun 30, 2024 | 129.78 Mn |
| Mar 31, 2024 | 134.96 Mn |
| Dec 31, 2023 | 135.58 Mn |
| Sep 30, 2023 | 141.85 Mn |
| Jun 30, 2023 | 146.76 Mn |
| Mar 31, 2023 | 145.17 Mn |
| Dec 31, 2022 | 135.12 Mn |
| Sep 30, 2022 | 142.49 Mn |
| Jun 30, 2022 | 150.74 Mn |
| Mar 31, 2022 | 152.21 Mn |
| Dec 31, 2021 | 146.37 Mn |
| Sep 30, 2021 | 150.82 Mn |
| Jun 30, 2021 | 157.15 Mn |
| Mar 31, 2021 | 75.81 Mn |
| Dec 31, 2020 | 46.30 Mn |
| Sep 30, 2020 | 27.24 Mn |
| Jun 30, 2020 | 24.68 Mn |
| Mar 31, 2020 | 24.79 Mn |
| Dec 31, 2019 | 25.96 Mn |
| Sep 30, 2019 | 20.29 Mn |
| Jun 30, 2019 | 21.19 Mn |
| Mar 31, 2019 | 17.18 Mn |
| Dec 31, 2018 | 19.46 Mn |
| Sep 30, 2018 | 22.32 Mn |
| Jun 30, 2018 | 23.59 Mn |
| Mar 31, 2018 | 22.48 Mn |
| Dec 31, 2017 | 25.55 Mn |
| Sep 30, 2017 | 25.88 Mn |
| Jun 30, 2017 | 23.45 Mn |
| Sep 30, 2016 | 6.31 Mn |
| Sep 30, 2015 | 12.81 Mn |
| Jun 30, 2015 | 6.57 Mn |
| Mar 31, 2015 | 4.70 Mn |
| Dec 31, 2014 | 473,126.00 |
| Sep 30, 2014 | 192,626.00 |
| Jun 30, 2014 | 7.41 Mn |
| Mar 31, 2014 | 8.41 Mn |
| Dec 31, 2013 | -1.67 Mn |
| Sep 30, 2013 | -2.46 Mn |
| Jun 30, 2013 | -3.55 Mn |
| Mar 31, 2013 | -3.43 Mn |
| Dec 31, 2012 | -3.33 Mn |
| Sep 30, 2012 | -2.88 Mn |
| Jun 30, 2012 | -2.20 Mn |
| Mar 31, 2012 | -2.93 Mn |
| Sep 30, 2011 | -1.14 Mn |
| Sep 30, 2010 | -2.96 Mn |